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Abstract
Background Acral lentiginous melanoma (ALM) occurs on the palms, soles and subungual surface and has poor
prognosis. It is uncommon in the Caucasian population and has remained unreported in East-Central Europe.
Objectives Our aim was to collect data from East-Central Europe by analysing the demographic and clinicopathologic
features of patients with ALM and comparing data with the reports in literature.
Methods We conducted a single-centre, retrospective review between 1976 and 2016 at one of the largest melanoma
referral centres in Hungary.
Results We identified 176 patients with ALM (3.83%) from 4593 patients with melanoma (mean age: 66.2 years). The
tumours were mainly located on the lower extremities (88.63%). The mean Breslow tumour thickness was 3.861 mm,
37.50% of the tumours were thicker than 4.00 mm, and 71.6% exhibited microscopic ulceration. Nearly one-third of the
patients underwent sentinel lymph node (SLN) biopsy, and 60.3% of the biopsies were positive for metastasis. The
positive SLN status was associated with significantly thick tumours and reduced survival. Patients with ALM had 5- and
10-year overall survival rates of 60.5% and 41.6%, respectively. The mean delay in diagnosis was 18 months after the
discovery of skin tumours. In multivariate analyses, age, tumour thickness and distant metastasis were independent risk
factors for poor survival (P < 0.001).
Conclusions Our study, which is the first single-centre report in East-Central Europe focusing on ALM, confirms that
patient and tumour characteristics and prognostic factors are similar with previous literature data involving Caucasians;
however, tumour thickness and survival suggest even worse prognosis.
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Introduction
Acral lentiginous melanoma (ALM) is a unique subtype of mela-
noma, which arises from the glabrous skin of the palms, soles
and nail apparatus.1–3 ALM is the least common subtype of cuta-
neous malignant melanoma (CMM) in Caucasians, accounting
for less than 10% of cases, but it is the most common melanoma
subtype in dark-skinned and Asian population.4–6
ALM has poor prognosis compared with other histologic sub-
types or anatomical locations of melanoma.4,7–9 Age, ulceration,
tumour thickness and tumour spread at diagnosis are substantial
prognostic factors in ALM.4,10–13 Given that these factors are
consistent with other CMM subtypes, the relatively poor prog-
nosis in ALM can be attributed to the delay in diagnosis.2,12 Mis-
diagnosis due to various clinical appearances, different
dermoscopic features, high rate of amelanosis and low awareness
can contribute to the delay in diagnosis.2,5,10,14,15
Clinical subtypes of melanoma have differences in pathogene-
sis and genetic background; however, ALM as a biologically
aggressive subtype remains debatable.16–19 Ultraviolet radiation
does not play a role in ALM pathogenesis. Compared with the
mutations in other CMM subtypes, activating BRAF and NRAS
mutations are less frequent in ALM (13–20% and 12–25%,
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respectively), whereas KIT mutations are more common (5–
36%).3,20–23
Published single institution case series and population-based
studies from different countries involving different skin types for
ALM are few, and none are available from the East-Central Eur-
ope region.1,2,4,6,10 Therefore, we chose to study the demo-
graphic and clinicopathological features and survival rates of
patients diagnosed with ALM at one of the dermato-oncological
referral centres in Hungary. We aimed to compare our results
with the data from the international literature for Caucasian
patients and to understand further this rare and aggressive sub-
type of cutaneous melanoma.
Patients and methods
This study is a retrospective review of patients diagnosed with
ALM at a single institution over a 40-year period (1976–2016).
It was conducted at the Department of Dermatology and Aller-
gology in Szeged and was approved by the ethics committee and
institutional review board of the University of Szeged in Hun-
gary. We investigated nearly 25 000 histopathology reports and
included only those patients for whom the diagnosis of ALM
was confirmed by histopathological examination and for whom
the melanoma was located on the glabrous skin (non-hair-bear-
ing skin) of the palms, soles or subungual area. Patients present-
ing melanoma at an acral location but not of an acral
lentiginous histological subtype were excluded from this study.
Clinical data of patients with ALM were collected from the indi-
vidual handwritten patient records (1976–1996) and from the
electronic database of our institute (1997–2016).
We aimed to collect and analyse data about the demographics
of the patients, clinical and histological characteristics of the pri-
mary tumour (location, macroscopic appearance, ulceration,
Breslow tumour thickness and Clark level), status of the sentinel
lymph node (SLN), stage of the disease (AJCC 8th ed.) and
details of the treatment.24 We were interested whether the mean
tumour thickness or the mean age of the patients with ALM has
changed in the diagnostic delay and in the prognostic factors of
ALM in our region over the investigated time period.
The survival probabilities were estimated by Kaplan–Meier
analysis. The differences in the survival of the groups were exam-
ined by a log-rank test with Bonferroni correction. The mean
Breslow tumour thickness between the SLN-positive and -nega-
tive groups was investigated by Student’s t-test. Meanwhile, the
trends during the examined time period in terms of age of the
patients and Breslow tumour thickness were analysed by Poisson
regression and ANOVA models. In addition, P < 0.05 was consid-
ered statistically significant. The influence of different risk fac-
tors on the survival was analysed using univariate and
multivariate Cox proportional hazard models. The risk factors
for survival were considered to be gender (male vs. female),
Clark invasion depth (II/III vs. IV/V), ulceration (absent vs. pre-
sent), dermal mitotic rate ≥ 1/mm2 (absent vs. present), tumour
site (hand vs. foot), status of SLN (negative vs. positive), nodal
status (negative vs. positive) and presence of distant metastases
(absent vs. present). Age and Breslow thickness were calculated
as continuous variables. Factors with P-values < 0.05 on uni-
variate analysis were included in multivariate analysis, whereas
P-value < 0.001 was considered to indicate statistical signifi-
cance. For the statistical analyses, R software (version 3.2.1) was
used.
Results
Between January 1976 and December 2016, 4593 patients were
diagnosed with CMM at our centre. Among them, 176 patients
had histologically confirmed ALM located on the palms, soles or
subungual area.
Patient’s demographics and primary tumour
characteristics
All patients were Caucasians. The mean age at diagnosis was
66.17 years (29–92, 12.97 years). Most of the cases (73.29%)
were diagnosed after 60 years old. The average age for males and
females was 64.50 (11.51) and 67.54 (13.93) years, respec-
tively. The male : female ratio was 1 : 1.26, and 55.68% of the
tumours occurred in female patients above 60 years old
(Table 1).
Of the 88.63% of tumours found on the lower extremities,
72.16% occurred on the soles and heels. Subungual melanoma
was diagnosed in 25 cases (14.21%).
The mean Breslow tumour thickness was 3.861 mm (0.000–
14.516, 2.66 mm); specifically, 75.00% of the tumours were
thicker than 2 mm, and 37.50% were thicker than 4 mm. Clark
invasion depth levels IV–V were described in 56.25% of the
tumours. Microscopic ulceration occurred in 126 cases
(71.59%), as observed by histological examination. Macroscopi-
cally, 35.79% of the tumours were ulcerated, and 14.20% were
bleeding (Fig. 1).
Sentinel lymph node biopsy (SLNB) has been performed
routinely at our centre since 1999. In our study group, 32.95%
of the patients underwent SLN biopsy, and 60.30% of these
biopsies were positive. SLN-negative patients were predomi-
nantly females (1 : 4), and these patients had significantly lower
mean Breslow tumour thickness and survival rates than SLN-
positive patients (2.02  0.36 mm vs. 4.66  0.45 mm;
P < 0.001). Meanwhile, no differences were observed between
the SLN-positive and -negative groups with respect to the mean
age of the patients, location of the tumours and amount of time
after noticing the tumour before consulting a physician (diag-
nostic delay).
Survival analysis
The 5- and 10-year overall survival rates of patients with ALM
were 60.51% (95% CI, 53.27–68.75) and 41.59% (95% CI,
34.10–50.72), respectively.
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Patients with ALM at tumour stage I had a significantly
(P < 0.001) better disease-specific survival rate than those at
tumour stages II, III and IV (Fig. 2). No significant differences
were noted in the disease-specific survival rates between patients
with stage II and III tumours, but both of these patient groups
had significantly (P < 0.001) better disease-specific survival rates
than those with stage IV tumour.
Analysis according to Breslow tumour thickness revealed that
the 5-year disease-specific survival rate of patients with T1
tumours was 92.31% (95% CI, 78.90–100.00), whereas that of
patients with T4 tumours was 28.56% (95% CI, 19.03–42.87). In
addition, patients with T4 tumours had significantly (P < 0.001)
worse disease-specific survival rates than those with T1–T3
tumours (Fig. 2).
The 5-year disease-specific survival rate in the SLN-negative
group (84.21%; 95% CI, 69.31–100.00) was significantly better
(P < 0.001) than that in the SLN-positive group (54.61%; 95%
CI, 39.95–74.65; Fig. 2).
The results of the Cox univariate and multivariate analyses for
disease-specific survival are shown in Table 2. In univariate anal-
ysis, age (P < 0.001), gender (P = 0.03), Breslow tumour thick-
ness (P < 0.001), Clark level (P < 0.001), ulceration (P < 0.001),
positive SLN (P = 0.004), positive nodal status (P = 0.008) and
presence of distant metastasis (P < 0.001) were statistically sig-
nificant (P < 0.05) and were, therefore, associated with worse
survival. On the other hand, dermal mitoses and anatomical sites
were not associated with worse survival. In subsequent multivari-
ate analysis, patients’ age [hazard ratio (HR) 1.058, 95% confi-
dence interval (CI) 1.035–1.083], Breslow tumour thickness (HR
1.187, 95% CI 1.099–1.282) and presence of distant metastasis
(HR 3.002, 95% CI 1.850–4.871) remained statistically significant
(P < 0.001) and became independent risk factors for survival.
Delay in the diagnosis of ALM
Of the 176 patients with ALM, 138 had data describing the delay
in the diagnosis. The delay between the time the patient noticed
the tumour, and the time of diagnosis was extremely variable
and ranged from 1 month to 10 years (mean time: 18 months).
Approximately half (51.45%) of the patients waited more than
1 year after noticing the skin lesion before seeking medical help.
Changes over four decades in the number of diagnosed
cases, Breslow thickness of the tumours and age of the
patients
During the 40 years of analysis, no significant change was noted
either in the mean Breslow tumour thickness (P = 0.964) of the
Table 1 Demographic and tumour characteristics of patients with
acral lentiginous melanoma (ALM) in the Hungarian study
Sex (n)
Male, n (%) 78 (44.32)
Female, n (%) 98 (55.68)
Male : female ratio 1 : 1.26
Age at diagnosis (year)
Range 29–92
Median 67.43
Mean (SD) 66.17 (12.97)
Mean age male (SD) 64.50 (11.51)
Mean age female (SD) 67.54 (13.93)
Location of the primary tumour
Upper extremity, n (%) 20 (11.37)
Palms 9 (5.12)
Nails 9 (5.12)
Other 2 (1.13)
Lower extremity, n (%) 156 (88.63)
Soles 86 (48.86)
Heels 41 (23.30)
Nails 16 (9.09)
Other 13 (7.38)
Breslow tumour thickness (mm)
Range 0.000–14.516
Median 3.344
Mean (SD) 3.861 (2.66)
Breslow tumour thickness, n (%)
≤1.00 mm 18 (10.23)
1.01–2.00 mm 26 (14.77)
2.01–4.00 mm 66 (37.50)
>4.00 mm 66 (37.50)
Clark level, n (%)
I 2 (1.14)
II 16 (9.09)
III 59 (33.52)
IV 68 (38.64)
V 31 (17.61)
Microscopic ulceration, n (%)
Present 126 (71.59)
Not present 47 (26.70)
No data 3 (1.71)
Delay in diagnosis, n (%) 138 (78.4)
<1 year 67 (48.55)
1–3 years 55 (39.86)
3–5 years 9 (6.52)
>5 years 7 (5.07)
n, number of the patients; SD, standard deviation.
Figure 1 Acral lentiginous melanoma (ALM) on the thumb
(71-year-old male, pT1a), great toe (44-year-old male, pT1a), palm
(85-year-old female, pT3b) and sole (81-year-old female, pT3b).
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tumours or in the mean age of the patients at the time of diag-
nosis (P = 0.157; Fig. 3). We diagnosed nearly the same number
of ALM cases in each decade. When analysing all patients with
CMM, we noticed a significant (P < 0.001) decrease in the pro-
portion of patients with ALM over the past 40 years, possibly
because of the dramatic increase of the superficial spreading
melanoma (SSM) subtype (Fig. 4).
Treatment of ALM patients
All 176 ALM patients in our study underwent wide local excision
of the primary tumour with different safety margins during the
study period of 40 years (Table S1). Regional lymph node dis-
section (RLND) was performed with an elective intent until
1998 in 24 patients (28.5%). From 1999, after the introduction
of SLN biopsy at our department, 58 patients with ALM
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Figure 2 Kaplan–Meier disease-specific survival curves and rates stratified by TNM stage (a), Breslow primary tumour thickness (b) and
SLN status (c) in our patients with acral lentiginous melanoma (ALM).
Table 2 Results of Cox proportional hazard models of covariates
Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Age 1.046 (1.027–1.065) <0.001 1.058 (1.035–1.083) <0.001
Female gender 0.652 (0.443–0.960) 0.030 0.506 (0.326–0.784) 0.002
Breslow thickness (mm) 1.253 (1.173–1.339) <0.001 1.187 (1.099–1.282) <0.001
Clark level IV/V (vs. II/III) 2.842 (1.871–4.316) <0.001 1.768 (1.071–2.918) 0.026
Presence of ulceration 3.625 (1.934–6.795) <0.001 2.591 (1.302–5.154) 0.006
Presence of dermal mitoses ≥1/mm2 1.149 (0.601–2.195) 0.674
Anatomical site: foot (vs. hand) 1.471 (0.714–3.032) 0.296
SLNB† positivity 6.087 (1.799–20.600) 0.004
Positive nodal status 1.714 (1.154–2.156) 0.008 2.585 (1.088–6.139) 0.031
Presence of distant metastasis 2.834 (1.840–4.364) <0.001 3.002 (1.850–4.871) <0.001
†Analysis of 58 patients.
Results of Cox proportional hazard models of covariates (significant P-value marked with bold).
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underwent SLNB, followed by complete RLND in 26 patients
(28.2%). In patients with clinically detectable lymph node
metastases, RLND was performed in 20 patients (23.8%) until
1998 and in seven patients (7.6%) from 1999. Regarding adju-
vant systemic treatment, dacarbazine was mainly used until 1998
(19.0%), whereas interferon-alpha (22.8%) was used from 1999.
For irresectable and/or metastatic disease, the systemic treatment
of choice was chemotherapy until 2015 (until 1998: 11.9%; from
1999: 20.6%). Since 2015, novel treatment options, such as tar-
get and immunooncological therapies, became available and
were used in a total of 14 patients (imatinib: 2; dabrafenib and
trametinib: 1; ipilimumab: 4; nivolumab: 4; pembrolizumab: 3).
Radiotherapy was used in 16.5% of our patients, either in an
adjuvant or a metastatic (cutaneous: 7; lymph node: 2; brain:
11) setting. From 2007, electrochemotherapy was performed in
2.2% of our patients for loco-regional cutaneous metastases of
melanoma. Based on the changes in the treatment strategies and
available drugs, we identified three important time periods
(1976–1998, 1999–2014 and 2015–2016) during the investigated
40 years. The sample size allowed us to compare the first two
periods. No statistically significant differences were observed
between the two groups with respect to demographic data (age,
male : female ratio and Breslow tumour thickness); however,
clinically detectable lymph node metastases (20 vs. 5 patients)
were numerically higher in the first group (1976–1998) than in
the second group (1999–2014). Using the Kaplan–Meier analy-
sis, 5- and 10-year overall survival rates were 74.33 (95% CI,
66.10–83.59) and 63.72 (54.36–74.70), respectively, with a signif-
icantly better (P < 0.001) survival in the patients treated
between 1999 and 2014 (Fig. S1).
Discussion
Acral lentiginous melanoma in Caucasians is a rare subtype of
CMM, accounting for less than 10% of all CMM cases.2,7 ALM
is often detected in advanced age and clinical stage and is associ-
ated with poor survival. During the past 40 years, 3.83% of the
4593 patients with CMM presenting at our department were
diagnosed with ALM. Our results confirmed that ALM mainly
affects elderly people, considering that most of the tumours
occurred at 70 years of age.2,4,7,8 Similar to the study of Ter-
amoto et al.,12 the mean age of the patients with ALM in the
present study was 66 years. Data in the literature concerning sex
predominance for ALM are conflicting.10 The study of Phan
et al.10 reported a female predominance in patients with ALM,
and female sex was an independent prognostic factor for sur-
vival. Other studies did not find significant sex differences in the
occurrence of ALM. In our study, the male : female ratio was
1 : 1.26.2,7,8
The mean Breslow tumour thickness of ALM tumours in our
study was nearly 4 mm, and 75% of the primary tumours were
thicker than 2 mm and were microscopically ulcerated. In more
than half of the tumours, the invasion depth was at Clark level
IV or V. In previous studies, the number of ALM lesions arising
on the foot was 5–16 times higher than that on the hand.10 In
our study, melanoma on the lower extremities was exhibited in
nearly 90% of the patients, occurring mainly on the soles
(48.86%) and heels (23.30%). Subungual melanoma is seemingly
more common on the fingernails than on the toenails.10 In our
study, 14.20% of the melanomas were subungual, appearing
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Figure 3 Distribution of the mean age at diagnosis (a) and Bres-
low primary tumour thickness (b) in our acral lentiginous melanoma
(ALM) cases during the past 40 years.
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Figure 4 Distribution of cutaneous melanoma by subtypes (4593
patients) during the past 40 years.
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mostly on the lower extremities. The mean age of patients with
ALM at the time of diagnosis and the location of the tumours in
our study were similar to the results published by other
authors.6,10,14 However, the mean Breslow tumour thickness was
significantly (P < 0.001) higher in our study than most in other
literature data for Caucasian patients.2,10,12,25
Patients with ALM have poor survival and unfavourable prog-
nosis. In the study of Bradford et al.,4 the 5- and 10-year overall
survival rates of patients with CMM are 91.3% and 87.5%,
respectively, whereas those of patients with ALM have signifi-
cantly worse survival rates. Comparing our results with other
studies involving Caucasians, we concluded that both the 5- and
10-year overall survival rates (70–80% and 56–67%, respectively)
of our patients with ALM are lower.4,8,10
After investigating the relationship between survival and the
TNM stage of the disease, we found that progression from one
stage to the next stage corresponded with significantly low
chances of survival, and this difference is the highest between
stages I and III and between stages I and IV. Therefore, survival
rate is highly influenced by the lymph node metastasis (stage III)
and presence of distant metastases (stage IV). With regard to
tumour thickness, the most significant difference in the survival
rate is found between the tumours thinner than 2 mm (T1–T2)
and the tumours thicker than 4 mm (T4). Tumours thicker than
4 mm correspond to a significantly lower survival rate in every
case than thinner tumours.
SLN biopsy has been performed routinely at our centre since
1999, and 32.95% of the patients in our study underwent SLN
biopsy. SLN-positive cases occurred at a significantly
(P < 0.001) higher proportion than the results from Pavri
et al.26
Delay in ALM diagnosis is well documented and is reportedly
greater than 7 months on average.10,15 Factors contributing to
the delay might include the age and/or the cognitive state of the
patients, hidden location, unusual clinical presentation, low
public awareness, and misdiagnosis and mistreatment by health-
care professionals, especially when pigmentation is absent. Rex
et al. and Teramoto et al. attributed the poor survival in patients
with ALM to the diagnostic delay rather than to a difference in
biological behaviour of this melanoma subtype.2,12 In our study,
more than half of the patients waited more than 1 year, and
nearly 12% waited more than 3 years before seeking medical
help. In a study by Phan et al.,10 the delay between the time the
patient first noticed the lesion and the time they were diagnosed
ranged from 2 months to 30 years; in our study, this delay ran-
ged from 1 month to 10 years.
Besides the parameters of malignant disease and patients’
characteristics, treatment is definitely the most important factor
that may influence the survival of melanoma sufferers. In
patients with malignant melanoma, treatment strategies changed
quite extensively during the investigated 40 years of our study.
Based on the Kaplan–Meier analysis, survival improved with the
introduction of new treatment strategies; however, due to the
various and constantly changing treatment options, major con-
clusions cannot be achieved from this analysis.
We compared our data with the literature for Caucasian
patients with ALM from Europe (Table 3). In all the chosen
studies, ALM occurred after 60 years old, with a female and
lower-extremity predominance. The mean Breslow tumour
thickness was greater than 2 mm in every study, but the thick-
ness (nearly 4 mm) observed in our country was second only to
that in the United Kingdom.2,12,15
Our study confirmed that patient and tumour characteristics
and prognostic factors are similar with those found in previous
literature data involving Caucasians; however, tumour thickness
and survival suggest even worse prognosis.7,8,10,25
More than 2000 new patients with melanoma are diagnosed
in Hungary annually, and one dies every day due to this malig-
nant disease [National Cancer Registry, http://www.ksh.hu].
Based on our observations at our dermato-oncology centre, the
number of patients diagnosed with melanoma increased dramat-
ically in the past few decades. This increase, especially with
respect to SSM and LMM, can be explained at least partially with
the increasing popularity of tanning and the lack of appropriate
photoprotection.
When analysing the tendencies of the past four decades, with
respect to the incidence of the disease, we diagnosed the same
number of ALM cases each decade, and we did not find major
Table 3 Comparison of our data with other studies involving Caucasians2,10,12,15
France (2006) Spain (2009) UK (2014) Germany (2017) Hungary (2019)
Duration period 1996–2004 1987–2007 1996–2006 1983–2015 1976–2016
N 126 89 87 2243 176
Non-Caucasian patients (n) Asian (1) Asian (2) – – –
Mean age (years) 63.0 61.6 67.0 63.1 66.2
Male : female ratio 1 : 1.86 1 : 1.69 1 : 1.71 1 : 1.48 1 : 1.26
Mean Breslow tumour
thickness (mm)
2.51 2.8 7.9 3.08 3.86
Location 87.3%, lower extremities 79.8%, lower extremities 84%, lower extremities 82.1%, feet 88.6%, lower extremities
37%, nails 24.7%, nails No data 35.6%, nails 14.2%, nails
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changes in the Breslow tumour thickness or in the mean age of
the patients at diagnosis. As UV-induced pathogenesis has
increased during this same period, this constant rate of diagnosis
is unlikely to be associated with UV exposure.
Our study, which is the first single-centre report in East-Cen-
tral Europe focusing on ALM, found that despite the improve-
ment in early diagnosis of melanoma and improved public
awareness in general, ALM in our region remains a subtype of
melanoma that is diagnosed with high Breslow tumour thickness
and advanced stage.27 Therefore, we would like to emphasize the
importance of early diagnosis of ALM by increasing disease
awareness through education and prevention programmes.
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